XNAS · HALO

+2.30% · +$2.46 · Vol 728.0K

Live · updated 11:53:13 ET

Halozyme Therapeutics, Inc.

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

$109.40

Card

Relationship Map

Follow $HALO

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $HALO by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measured

Thu Oct 1 · last completed session · daily score · 18h old · HALO

Methodology

HALO

Halozyme Therapeutics, Inc.

Thu Oct 1 · last completed session · daily score · 18h old

74/100

Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

74/ 100

Veridion Score

Upper range · MEDIUM confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 1 · last completed session · daily score · 18h old

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is HALO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move HALO next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4 / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Oct 1
Score
Score moved -6
80/Highest qualified -> 74/Upper range
Veridion score historySource
Sep 17
Form 4Checking access
Posard Matthew L. Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Sep 11
Form 4Checking access
Torley Helen Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 19
Form 4Checking access
Torley Helen Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 11
Form 4Checking access
Connaughton Bernadette Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 9
Form 4Checking access
Torley Helen Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Mar 9
CongressChecking access
Gilbert Ray Cisneros, Jr. purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 24
CongressChecking access
Gilbert Ray Cisneros, Jr. sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Sep 9
CongressChecking access
Josh Gottheimer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 12
CongressChecking access
Daniel S. Goldman sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Halozyme Therapeutics, Inc.

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2004

Employees

423

Country

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$106.96

Day high

$109.45

Day low

$106.65

Previous close

$106.94

52W high

$115.22

-5.05% from high

52W low

$61.63

89% of range

Market cap

$12.1B

Beta

0.28

Shares out

113.5M

Volume

728K

0.33× rel vol

Avg volume

2.2M

VWAP

$108.26

Price history computed in-house

-3.95%

-0.24%

+37.70%

+52.60%

YTD

+62.56%

SMA 50 $102.35 · above

SMA 200 $78.10 · above

52W position 89%

HALO overview

Veridion Score

Registered · 2026-10-01

6 of 6 factors measured

Latest receipt rows

Gilbert Ray Cisneros, Jr. · Purchase

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around HALO.Congress disclosuresOpen receipt and filing context for HALO.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

HALO insider activity

Halozyme Therapeutics, Inc.

Score

74 · Upper range

Pressure

Net selling

Filings

Buys / sells

0 / 25

Net value

-$15.1M

Insiders

Named filers

Posard Matthew L.

Director

Board

Torley Helen

Director · PRESIDENT AND CEO

Board

Connaughton Bernadette

Director

Board

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$15.1M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-09-17	2026-09-16	Posard Matthew L.	Director	sell	$108.04	8,896	62,839	$961K	SEC Form 4
2026-09-17	2026-09-16	Posard Matthew L.	Director	sell	$108.99	4,000	58,839	$436K	SEC Form 4
2026-09-17	2026-09-16	Posard Matthew L.	Director	sell	$106.13	3,100	74,735	$329K	SEC Form 4